ARCHIVES

Mendelsohn Defends ImClone’s Actions And His Role In Development of C225

This article is from The Cancer Letter archive.

Vol. 28 No. 38 | October 18, 2002

Download PDF Visit The Full Archive

Related Articles

Michigan Scientist David Beer Sought Retraction Of Potti’s NEJM Paper Over Misuse Of His Data

July 30, 2010

In Brief: Parkinson To Leave CTEP For Novartis; FTC To Permit Sandoz, Ciba-Geigy Merger

January 10, 1997

Study: Women at Higher Risk Of Estrogen Receptor Positive Breast Cancer After Smoking

February 28, 2014

NCI Program Develops Bioinformatics Tool To Design Cancer Drugs

September 13, 2002

Blinatumomab Demonstrates High Response Rate in ALL

June 29, 2012

Agents Not Indicated In Curative Setting.

August 8, 2008